Omeros Corp Offers 26.6% Annualized Return on $10 Strike Put Options
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Should l Buy OMER?
Source: NASDAQ.COM
- Options Yield Analysis: Omeros Corp's $10 strike put options offer a 26.6% annualized return, although they will only be exercised if the stock price declines by 35.1%, resulting in a cost basis of $9 per share, highlighting the delicate balance between risk and reward in options trading.
- Market Volatility Consideration: With a trailing twelve-month volatility of 146%, Omeros's stock price history provides a foundation for investors to assess the viability of selling put options, aiding in the evaluation of whether the potential returns justify the associated risks under current market conditions.
- Investment Strategy Recommendation: Given Omeros's current stock price of $15.34, the potential returns from selling options must be weighed against fundamental analysis to ensure investors make informed decisions and avoid unnecessary losses.
- Options Market Dynamics: While the only benefit for put sellers comes from collecting the premium, investors must carefully evaluate whether the potential downside risks are worth the trade-off in a highly volatile market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMER
Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.440
Low
36.00
Averages
43.67
High
55.00
Current: 13.440
Low
36.00
Averages
43.67
High
55.00
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Omeros Corp's Yartemlea Receives J-Code Support
- J-Code Empowerment: Omeros Corp. announced that its treatment Yartemlea has received a permanent J-code effective July 1, which will simplify claims processing for hospitals and clinics, thereby reducing administrative burdens and accelerating patient access to treatment.
- Positive Market Reaction: Omeros shares have surged approximately 97% over the past 12 months, and are on track for their best week since December, reflecting investor optimism regarding the impact of the J-code on commercial acceleration.
- European Approval Prospects: The company is eyeing approval for Yartemlea from the European Medicines Agency by mid-2026, which could enhance its competitive position in the global rare disease treatment market and expand its international footprint.
- Strategic Collaboration Potential: The asset purchase and licensing agreement with Danish pharmaceutical company Novo Nordisk could yield up to $2.1 billion for Omeros, including milestone payments, highlighting its strategic positioning in the rare blood and kidney disorders space.
See More
Sagimet Biosciences Appoints New Chief Medical Officer
- Executive Change: Sagimet Biosciences Inc. announced the appointment of Andreas Grauer as Chief Medical Officer effective April 20, aiming to enhance the advancement of its FASN inhibitor pipeline and broader clinical development programs.
- Experienced Leader: Andreas Grauer brings over two decades of experience in clinical development, medical affairs, and regulatory strategy, having most recently served as Chief Medical Officer at Omeros Corp., which is expected to provide valuable industry insights to Sagimet.
- Former CMO Support: Eduardo Bruno Martins has retired but will continue to support the company as an external scientific advisor, ensuring continuity of knowledge and smooth progression of ongoing projects.
- Market Reaction: In pre-market trading on Nasdaq, Sagimet Biosciences' stock fell by 0.31% to $6.45, while Omeros' stock also decreased by 0.22% to $13.41, reflecting market caution regarding the executive change.
See More
Omeros Corporation Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Performance: Omeros Corporation reported a net income of $86.5 million for Q4 2025, a significant turnaround from a net loss of $31.4 million in the previous year, primarily driven by its partnership with Novo Nordisk, highlighting the company's improved profitability.
- Impact of Partnership: The exclusive global rights deal with Danish pharmaceutical giant Novo, valued at up to $2.1 billion, resulted in a net gain of $237.6 million for Omeros, including $240 million in upfront cash, underscoring the market potential in rare disease therapies.
- Non-GAAP EPS Exceeds Expectations: Omeros reported a non-GAAP EPS of $3.14, surpassing consensus estimates by $2.78, reflecting strong financial management and profitability, which further boosts investor confidence.
- Future Development Plans: Omeros anticipates that its newly approved transplant therapy, Yartemlea, will achieve financial self-sustainability by 2026 and aims for positive cash flow by 2027, indicating confidence in future growth and strategic positioning.
See More
Omeros Corporation Q4 2025 Earnings Call Highlights
- Successful Transaction: Omeros completed its asset purchase agreement with Novo Nordisk on November 25, bringing in $240 million upfront and potential milestone payments up to $2.1 billion, significantly enhancing the company's financial strength and competitive position in the market.
- FDA Approval: On December 23, Omeros received FDA approval for narsoplimab, commercialized as YARTEMLEA, with no vaccination requirements, allowing for rapid sales initiation that is expected to increase the company's market share in transplant therapies.
- Financial Performance: Omeros reported a net income of $86.5 million for Q4, translating to $1.22 per share, a significant improvement from the net loss in Q3, indicating strong growth potential following the launch of new products.
- Future Outlook: Management anticipates that YARTEMLEA will achieve financial self-sustainability in 2026 and expects to reach positive cash flow by 2027, although no specific sales targets were provided in the near term, reflecting cautious optimism about market acceptance.
See More
Omeros Reports Significant Q4 Turnaround with $86.5M Net Income
- Successful Asset Transaction: Omeros closed a significant asset purchase and licensing deal with Novo Nordisk valued at up to $2.1 billion, providing a $240 million upfront payment that will bolster the company's future R&D and market expansion efforts.
- FDA Approval Milestone: The FDA's approval of YARTEMLEA as the first and only treatment for TA-TMA marks a significant breakthrough for the company in the biopharmaceutical sector, expected to drive sales growth moving forward.
- Improved Financial Performance: Omeros reported a net income of $86.5 million for Q4 2025, a substantial turnaround from a net loss of $30.9 million in the previous quarter, indicating a strong recovery in business operations and enhanced profitability.
- Debt Management Optimization: The company successfully repaid a significant portion of its debt, leaving only $70.8 million in outstanding convertible notes, which significantly improves its balance sheet and lays a foundation for future financial sustainability.
See More
Omeros Reports Strong Q4 Results with Novo Nordisk Deal
- Significant Transaction Gains: Omeros reported a net gain of $237.6 million in Q4 due to the zaltenibart transaction with Novo Nordisk, which is valued at up to $2.1 billion, marking a major advancement in the biopharmaceutical sector.
- FDA Approval for New Drug: Yartemlea received FDA approval in December for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, with commercial sales starting in January, expected to significantly boost revenue and market share.
- Positive Market Reaction: Omeros shares rose 5% in after-hours trading, reflecting investor optimism regarding the partnership with Novo Nordisk and other drug prospects, with a 28% increase in stock price over the past year indicating growing market confidence.
- Optimistic Future Outlook: The company anticipates approval from the European Medicines Agency by mid-2026, with the CEO stating that the partnership with Novo will provide ongoing operating capital, supporting the development of future product portfolios and aiming for positive cash flow by 2027.
See More
Omeros Corp's Yartemlea Receives J-Code Support
- J-Code Empowerment: Omeros Corp. announced that its treatment Yartemlea has received a permanent J-code effective July 1, which will simplify claims processing for hospitals and clinics, thereby reducing administrative burdens and accelerating patient access to treatment.
- Positive Market Reaction: Omeros shares have surged approximately 97% over the past 12 months, and are on track for their best week since December, reflecting investor optimism regarding the impact of the J-code on commercial acceleration.
- European Approval Prospects: The company is eyeing approval for Yartemlea from the European Medicines Agency by mid-2026, which could enhance its competitive position in the global rare disease treatment market and expand its international footprint.
- Strategic Collaboration Potential: The asset purchase and licensing agreement with Danish pharmaceutical company Novo Nordisk could yield up to $2.1 billion for Omeros, including milestone payments, highlighting its strategic positioning in the rare blood and kidney disorders space.
See More
Sagimet Biosciences Appoints New Chief Medical Officer
- Executive Change: Sagimet Biosciences Inc. announced the appointment of Andreas Grauer as Chief Medical Officer effective April 20, aiming to enhance the advancement of its FASN inhibitor pipeline and broader clinical development programs.
- Experienced Leader: Andreas Grauer brings over two decades of experience in clinical development, medical affairs, and regulatory strategy, having most recently served as Chief Medical Officer at Omeros Corp., which is expected to provide valuable industry insights to Sagimet.
- Former CMO Support: Eduardo Bruno Martins has retired but will continue to support the company as an external scientific advisor, ensuring continuity of knowledge and smooth progression of ongoing projects.
- Market Reaction: In pre-market trading on Nasdaq, Sagimet Biosciences' stock fell by 0.31% to $6.45, while Omeros' stock also decreased by 0.22% to $13.41, reflecting market caution regarding the executive change.
See More
Omeros Corporation Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Performance: Omeros Corporation reported a net income of $86.5 million for Q4 2025, a significant turnaround from a net loss of $31.4 million in the previous year, primarily driven by its partnership with Novo Nordisk, highlighting the company's improved profitability.
- Impact of Partnership: The exclusive global rights deal with Danish pharmaceutical giant Novo, valued at up to $2.1 billion, resulted in a net gain of $237.6 million for Omeros, including $240 million in upfront cash, underscoring the market potential in rare disease therapies.
- Non-GAAP EPS Exceeds Expectations: Omeros reported a non-GAAP EPS of $3.14, surpassing consensus estimates by $2.78, reflecting strong financial management and profitability, which further boosts investor confidence.
- Future Development Plans: Omeros anticipates that its newly approved transplant therapy, Yartemlea, will achieve financial self-sustainability by 2026 and aims for positive cash flow by 2027, indicating confidence in future growth and strategic positioning.
See More
Omeros Corporation Q4 2025 Earnings Call Highlights
- Successful Transaction: Omeros completed its asset purchase agreement with Novo Nordisk on November 25, bringing in $240 million upfront and potential milestone payments up to $2.1 billion, significantly enhancing the company's financial strength and competitive position in the market.
- FDA Approval: On December 23, Omeros received FDA approval for narsoplimab, commercialized as YARTEMLEA, with no vaccination requirements, allowing for rapid sales initiation that is expected to increase the company's market share in transplant therapies.
- Financial Performance: Omeros reported a net income of $86.5 million for Q4, translating to $1.22 per share, a significant improvement from the net loss in Q3, indicating strong growth potential following the launch of new products.
- Future Outlook: Management anticipates that YARTEMLEA will achieve financial self-sustainability in 2026 and expects to reach positive cash flow by 2027, although no specific sales targets were provided in the near term, reflecting cautious optimism about market acceptance.
See More
Omeros Reports Significant Q4 Turnaround with $86.5M Net Income
- Successful Asset Transaction: Omeros closed a significant asset purchase and licensing deal with Novo Nordisk valued at up to $2.1 billion, providing a $240 million upfront payment that will bolster the company's future R&D and market expansion efforts.
- FDA Approval Milestone: The FDA's approval of YARTEMLEA as the first and only treatment for TA-TMA marks a significant breakthrough for the company in the biopharmaceutical sector, expected to drive sales growth moving forward.
- Improved Financial Performance: Omeros reported a net income of $86.5 million for Q4 2025, a substantial turnaround from a net loss of $30.9 million in the previous quarter, indicating a strong recovery in business operations and enhanced profitability.
- Debt Management Optimization: The company successfully repaid a significant portion of its debt, leaving only $70.8 million in outstanding convertible notes, which significantly improves its balance sheet and lays a foundation for future financial sustainability.
See More
Omeros Reports Strong Q4 Results with Novo Nordisk Deal
- Significant Transaction Gains: Omeros reported a net gain of $237.6 million in Q4 due to the zaltenibart transaction with Novo Nordisk, which is valued at up to $2.1 billion, marking a major advancement in the biopharmaceutical sector.
- FDA Approval for New Drug: Yartemlea received FDA approval in December for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, with commercial sales starting in January, expected to significantly boost revenue and market share.
- Positive Market Reaction: Omeros shares rose 5% in after-hours trading, reflecting investor optimism regarding the partnership with Novo Nordisk and other drug prospects, with a 28% increase in stock price over the past year indicating growing market confidence.
- Optimistic Future Outlook: The company anticipates approval from the European Medicines Agency by mid-2026, with the CEO stating that the partnership with Novo will provide ongoing operating capital, supporting the development of future product portfolios and aiming for positive cash flow by 2027.
See More
